Aprea Therapeutics (APRE)
(Delayed Data from NSDQ)
$5.35 USD
+0.18 (3.48%)
Updated Apr 25, 2024 03:26 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
APRE 5.35 +0.18(3.48%)
Will APRE be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for APRE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for APRE
Jazz Pharma (JAZZ) Gets EU Nod for Cancer Drug Enrylaze
FDA Accepts Merck (MRK) sNDA for Welireg in Renal Cell Carcinoma
APRE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bears are Losing Control Over Aprea Therapeutics, Inc. (APRE), Here's Why It's a 'Buy' Now
All You Need to Know About Aprea Therapeutics, Inc. (APRE) Rating Upgrade to Buy
Aprea (APRE) Rises on Advancing Lead Drug to Clinical Studies
Other News for APRE
Aprea Therapeutics’ Promising Cancer Drug Candidate Warrants Buy Rating
Optimistic Outlook for Aprea Therapeutics’ Oncology Pipeline: A Comprehensive Buy Rating Analysis
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Aprea Therapeutics files to sell 4.39M shares of common stock for holders